Pulmonary Hypertension

In June 2017, Actelion became part of the Janssen Pharmaceutical Companies of Johnson & Johnson. In February 2019, Janssen Sciences Ireland acquired the Irish operations of Actelion.

Pulmonary hypertension (PH) is a rare and incurable progressive disease that causes high blood pressure in the blood vessels connecting the heart and lungs.1,2 There are five groups of PH, as defined by the World Health Organization (WHO).1 Our focus has been on a specific, rare form of PH (WHO Group 1) called pulmonary arterial hypertension (PAH), but our research covers other groups of PH too.1

Our goal is to give people with PH a manageable condition.

At Janssen, we are spearheading a new era for PH, working to transform the disease into a long-term manageable condition, so that patients can live a normal life. We are working to reach more patients and aim to help tackle the diagnosis gap that is delaying access to the care that patients need.

Our pioneering medicines have contributed to improved patient outcomes for PAH communities. Our deep understanding of the complex pathways and molecular mechanisms involved in PAH has resulted in the development of tailored medicines that have improved patient outcomes.

References

1. Humbert M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal 2022.

2. PHA UK. About PH. Available at https://www.phauk.org/what-is-ph/ Last accessed May 2022.

CP-405408 | August 2023